Although investment in pharma R&D continues to
increase, approval of new drugs remains relatively low. This
productivity crisis presents new challenges to biopharma R&D in
terms of resource management, forecasting, and capacity planning. To
counteract the decline in new therapeutics and high risk of product
failure, biopharma must adapt with improved performance planning,
intelligent outsourcing, and new big data analytics aimed at developing
strategic and flexible resource management systems.
In an environment of declining revenues and
uncertain commercial success, biopharma, device and R&D companies
need to continuously evaluate their portfolios. Manufacturers must make
tough decisions about which products and projects to pursue to optimize
long-term revenue and reduce overall risk.
Cambridge Healthtech Institute’s and the BioPharma Strategy Series’ 15th Annual Strategic Resource Management and 12th Annual Portfolio Management Executive Forum
attracts 100 senior R&D executives from the pharma, biotech,
device, IT, public and governmental communities who share best practices
in project and portfolio management, R&D innovation, decision
analysis, forecasting and the improvement of operational models.